Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things podcast: US Medicare price negotiations get soft landing; Medicare negotiations and patent cliff acceleration; Novo Nordisk steps into heart failure; PCSK9s and the convenience battle; and an investor’s view of Korean biotech potential.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 1 September 2023, including: US Medicare price negotiations get soft landing; Medicare negotiations and patent cliff acceleration; Novo Nordisk A/S steps into heart failure; PCSK9s and the convenience battle; and one investor’s view of Korean biotech potential.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "First Round Of Drugs Up For Medicare Negotiation Gets Soft Landing" - Scrip, 29 Aug, 2023.)
(Also see "Patent Cliff Likely Accelerated By Two Years For Most Drugs On Medicare Price Negotiation List" - Scrip, 29 Aug, 2023.)
(Also see "Novo Nordisk STEPs Into Heart Failure" - Scrip, 25 Aug, 2023.)
(Also see "Merck’s Anti-PCSK9 Pill Sets Up Convenience Battle Against Infrequently Dosed Injectables" - Scrip, 25 Aug, 2023.)
(Also see "Novo Holdings’ Jee On Korea's Potential As Next Global Biotech Player" - Scrip, 28 Aug, 2023.)